Mosunetuzumab Monotherapy Demonstrates Durable Efficacy With a Manageable Safety Profile in Patients With Relapsed/Refractory Follicular Lymphoma who Received ≥2 Prior Therapies: Updated Results From a Pivotal Phase II Study

被引：0
|
作者：
Bartlett, Nancy L. [1 ]
Sehn, Laurie H. [2 ,3 ]
Matasar, Matthew [4 ]
Schuster, Stephen J. [5 ]
Assouline, Sarit [6 ]
Giri, Pratyush [7 ]
Kuruvilla, John [8 ]
Canales, Miguel [9 ]
Dietrich, Sascha [10 ]
Fay, Keith [11 ,12 ]
Ku, Matthew [13 ]
Nastoupil, Loretta [14 ]
Wei, Michael C. [15 ]
Yin, Shen [15 ]
To, Iris [15 ]
Huang, Huang [16 ]
Min, Juliana [17 ]
Bolen, Christopher R. [15 ]
Penuel, Elicia [15 ]
Budde, L. Elizabeth [18 ]
机构：
[1] Washington Univ, Siteman Canc Ctr, Sch Med, St Louis, MO USA
[2] BC Canc Ctr Lymphoid Canc, Vancouver, BC, Canada
[3] Univ British Columbia, Vancouver, BC, Canada
[4] Mem Sloan Kettering Canc Ctr, New York, NY USA
[5] Univ Penn, Lymphoma Program, Abramson Canc Ctr, Philadelphia, PA USA
[6] McGill Univ, Jewish Gen Hosp, Montreal, PQ, Canada
[7] Royal Adelaide Hosp, Adelaide, SA, Australia
[8] Princess Margaret Canc Ctr, Toronto, ON, Canada
[9] Hosp Univ La Paz, Madrid, Spain
[10] Heidelberg Univ, Heidelberg, Germany
[11] St Vincents Hosp, Sydney, NSW, Australia
[12] Royal North Shore Hosp, Sydney, NSW, Australia
[13] Univ Melbourne, St Vincents Hosp, Melbourne, Australia
[14] MD Anderson Canc Ctr, Houston, TX USA
[15] Genentech Inc, San Francisco, CA USA
[16] Hoffmann La Roche Ltd, Mississauga, ON, Canada
[17] Roche Prod Ltd, Welwyn Garden City, Herts, England
[18] City Hope Natl Med Ctr, Duarte, CA USA
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷
关键词：
IBCL; mosunetuzumab; bispecific antibody; relapsed/refractory; follicular lymphoma; Phase II;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
IBCL-458
引用
收藏
页码：S453 / S453
页数：1
相关论文
共 50 条
  • [41] Revumenib Monotherapy in Patients with Relapsed/Refractory KMT2Ar Acute Leukemia: Topline Efficacy and Safety Results from the Pivotal Augment-101 Phase 2 Study
    Aldoss, Ibrahim
    Issa, Ghayas C.
    Thirman, Michael
    DiPersio, John
    Arellano, Martha
    Blachly, James S.
    Mannis, Gabriel N.
    Perl, Alexander
    Dickens, David S.
    McMahon, Christine M.
    Traer, Elie
    Zwaan, C. Michel
    Grove, Carolyn
    Stone, Richard
    Shami, Paul J.
    Mantzaris, Ioannis
    Greenwood, Matthew
    Shukla, Neerav
    Cuglievan, Branko
    Gu, Yu
    Bagley, Rebecca G.
    Madigan, Kate
    Sunkaraneni, Soujanya
    Huy Van Nguyen
    McNeer, Nicole
    Stein, Eytan M.
    BLOOD, 2024, 144
  • [42] Orelabrutinib Monotherapy in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Updated Long Term Results of Phase II Study
    Xu, Wei
    Song, Yongping
    Wang, Tingyu
    Yang, Shenmiao
    Liu, Lihong
    Hu, Yu
    Zhang, Wei
    Zhou, Jianfeng
    Gao, Sujun
    Ding, Kaiyang
    Zhang, Huilai
    Zhu, Zunmin
    Wang, Shunqing
    Xu, Bing
    Hu, Jianda
    Liu, Ting
    Ji, Chunyan
    Xia, Zhongjun
    Li, Yan
    Wang, Xin
    Bin Zhang
    Zhao, Renbin
    Li, Jianyong
    BLOOD, 2021, 138
  • [43] Glofitamab in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and ≥ 2 prior therapies: Pivotal phase II expansion results.
    Dickinson, Michael
    Carlo-Stella, Carmelo
    Morschhauser, Franck
    Bachy, Emmanuel
    Corradini, Paolo
    Iacoboni, Gloria
    Khan, Cyrus
    Wrobel, Tomasz
    Offner, Fritz
    Trneny, Marek
    Wu, Shang-Ju
    Cartron, Guillaume
    Hertzberg, Mark
    Balari, Anna Sureda
    Perez-Callejo, David
    Lundberg, Linda
    Relf, James
    Clark, Emma
    Humphrey, Kathryn
    Hutchings, Martin
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [44] Safety and Efficacy of Orelabrutinib Monotherapy in Chinese Patients with Relapsed or Refractory Mantle Cell Lymphoma: A Multicenter, Open-Label, Phase II Study
    Song, Yuqin
    Song, Yongping
    Liu, Lihong
    Zhang, Mingzhi
    Li, Zhiming
    Ji, Chunyan
    Xu, Wei
    Liu, Ting
    Xu, Bing
    Wang, Xin
    Gao, Sujun
    Zhang, Huilai
    Hu, Yu
    Li, Yan
    Cheng, Ying
    Yang, Haiyan
    Cao, Junning
    Zhu, Zunmin
    Hu, Jianda
    Zhang, Wei
    Jing, Hongmei
    Ding, Kaiyang
    Lu, Zhengguang
    Zhang, Bin
    Zhao, Renbin
    Xu, Zhixin
    Zhu, Jun
    BLOOD, 2019, 134
  • [45] Efficacy and Safety of Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Mantle Cell Lymphoma in the Phase 2 ACE-LY-004 Study
    Wang, Michael
    Rule, Simon
    Zinzani, Pier Luigi
    Goy, Andre
    Casasnovas, Rene-Olivier
    Smith, Stephen D.
    Damaj, Gandhi
    Doorduijn, Jeanette K.
    Lamy, Thierry
    Morschhauser, Franck
    Panizo, Carlos
    Shah, Bijal
    Davies, Andrew
    Eek, Richard
    Dupuis, Jehan
    Jacobsen, Eric
    Kater, Arnon P.
    Le Gouill, Steven
    Oberic, Lucie
    Robak, Tadeusz
    Covey, Todd
    Dua, Richa
    Hamdy, Ahmed
    Huang, Xin
    Izumi, Raquel
    Patel, Priti
    Slatter, J. Greg
    Jurczak, Wojciech
    BLOOD, 2017, 130
  • [46] Odronextamab in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) Grade 1-3a: Results from a Prespecified Analysis of the Pivotal Phase II Study ELM-2
    Kim, Tae Min
    Taszner, Michal
    Cho, Seok-Goo
    Novelli, Silvana
    Le Gouill, Steven
    Poon, Michelle Limei
    Villasboas, Jose C.
    Champion, Rebecca
    Bachy, Emmanuel
    Guidez, Stephanie
    Alonso, Aranzazu Alonso
    Jagadeesh, Deepa
    Merli, Michele
    Tucker, David
    Cai, Jingxian
    De Oliveira, Carolina Leite
    Zhu, Min
    Chaudhry, Aafia
    Mohamed, Hesham
    Ambati, Srikanth R.
    Luminari, Stefano
    BLOOD, 2022, 140 : 2280 - 2282
  • [47] Updated Results from the Phase II Study of Orelabrutinib Monotherapy in Chinese Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Cell Leukemia
    Xu, Wei
    Song, Yongping
    Wang, Tingyu
    Yang, Shenmiao
    Liu, Lihong
    Hu, Yu
    Zhang, Wei
    Zhou, Jianfeng
    Gao, Sujun
    Ding, Kaiyang
    Zhang, Huilai
    Zhu, Zunmin
    Wang, Shun-Qing
    Xu, Bing
    Hu, Jianda
    Liu, Ting
    Ji, Chunyan
    Xia, Zhongjun
    Li, Yan
    Wang, Xin
    Zhu, Huaqiang
    Zhao, Renbin
    Zhang, Bin
    Xu, Zhixin
    Li, Jianyong
    BLOOD, 2020, 136
  • [48] Ibrutinib as Treatment for Patients With Relapsed/Refractory Follicular Lymphoma: Results From the Open-Label, Multicenter, Phase II DAWN Study
    Gopal, Ajay K.
    Schuster, Stephen J.
    Fowler, Nathan H.
    Trotman, Judith
    Hess, Georg
    Hou, Jing-Zhou
    Yacoub, Abdulraheem
    Lill, Michael
    Martin, Peter
    Vitolo, Umberto
    Spencer, Andrew
    Radford, John
    Jurczak, Wojciech
    Morton, James
    Caballero, Dolores
    Deshpande, Sanjay
    Gartenberg, Gary J.
    Wang, Shean-Sheng
    Damle, Rajendra N.
    Schaffer, Michael
    Balasubramanian, Sriram
    Vermeulen, Jessica
    Cheson, Bruce D.
    Salles, Gilles
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (23) : 2405 - +
  • [49] Tanespimycin plus Bortezomib Demonstrates Safety, Activity, and Effective Target Inhibition in Relapsed/Refractory Myeloma Patients: Updated Results of a Phase 1/2 Study
    Richardson, Paul G.
    Chanan-Khan, Asher A.
    Lonial, Sagar
    Krishnan, Amrita Y.
    Carroll, Michael P.
    Albitar, Maher
    Kopit, Justin
    Berman, David
    Anderson, Kenneth C.
    BLOOD, 2009, 114 (22) : 1128 - 1129
  • [50] Mosunetuzumab with Polatuzumab Vedotin Is Effective and Has a Manageable Safety Profile in Patients Aged <65 and ≥65 Years with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) and ≥1 Prior Therapy: Subgroup Analysis of a Phase Ib/II Study
    Olszewski, Adam J.
    Budde, L. Elizabeth
    Chavez, Julio
    Ghosh, Nilanjan
    Kamdar, Manali
    Lossos, Izidore S.
    Diefenbach, Catherine
    Sabry, Waleed
    Dorritie, Kathleen
    Huw, Ling-Yuh
    Pham, Song
    Jia, Ting
    Wu, Hao
    To, Iris
    Wei, Michael C.
    Assouline, Sarit
    BLOOD, 2022, 140 : 3757 - 3758
12345